Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% above fair value
$0.82+0.02 (+2.60%)
Close on Nov 17, 2026Market cap $206.32MP/E –Yield –
Lineage Cell Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Lineage Cell Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$23.82M. For fiscal 2025 it was -$18.92M. The highest annual figure on record is $1.06M in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$18.92M | – |
| FY2024 | Dec 31, 2024 | -$23.09M | – |
| FY2023 | Dec 31, 2023 | -$28.57M | -2797.5% |
| FY2022 | Dec 31, 2022 | $1.06M | – |
| FY2021 | Dec 31, 2021 | -$23.56M | – |
| FY2020 | Dec 31, 2020 | -$19.75M | – |
| FY2019 | Dec 31, 2019 | -$31.95M | – |
| FY2018 | Dec 31, 2018 | -$30.88M | – |
| FY2017 | Dec 31, 2017 | -$30.52M | – |
| FY2016 | Dec 31, 2016 | -$42.33M | – |
| FY2015 | Dec 31, 2015 | -$44.54M | – |
| FY2014 | Dec 31, 2014 | -$38.85M | – |
| FY2013 | Dec 31, 2013 | -$29.51M | – |
| FY2012 | Dec 31, 2012 | -$19.68M | – |
| FY2011 | Dec 31, 2011 | -$13.59M | – |
| FY2010 | Dec 31, 2010 | -$7.73M | – |
| FY2009 | Dec 31, 2009 | -$4.26M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.24M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.08M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.88M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.62M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.54M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.89M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.35M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.79M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.18M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.78M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.02M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.04M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.27M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.24M | -151.3% |
| Q4 FY2022 | Dec 31, 2022 | -$8.30M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.48M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.06M | – |
| Q1 FY2022 | Mar 31, 2022 | $21.90M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.87M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.85M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.42M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.42M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.64M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.85M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.24M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.03M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.52M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.44M | – |
| Q2 FY2019 | Jun 30, 2019 | -$9.67M | – |
| Q1 FY2019 | Mar 31, 2019 | -$9.31M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.81M | – |
| Q3 FY2018 | Sep 30, 2018 | -$7.33M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.40M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.34M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.68M | – |
| Q3 FY2017 | Sep 30, 2017 | -$7.68M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.06M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.10M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.85M | – |
| Q3 FY2016 | Sep 30, 2016 | -$8.92M | – |
See a number that looks wrong?